Organization (Other)
Roswell Park Cancer Institute Corporation
ClinicalTrials.gov lists Roswell Park Cancer Institute Corporation as lead sponsor of 416 trials. It has 629 active development programs and 151 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 31 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 30 in 2026 and about 26 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 31 already registered with a 2026 start date: at the cutoff, 7 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.
This page covers Roswell Park Cancer Institute Corporation: 416 lead-sponsored trials and 1 legal-entity registration.
Disease areas (203)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 53 |
| Head and Neck Neoplasms | 40 |
| Carcinoma, Non-Small-Cell Lung | 38 |
| Colorectal Neoplasms | 34 |
| Lymphoma | 34 |
Showing 5 of 203 disease areas.
Trials by start year as sponsor or collaborator (36)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 31 |
| 2025 | 18 |
| 2024 | 20 |
| 2023 | 18 |
| 2022 | 12 |
| 2021 | 16 |
| 2020 | 12 |
| 2019 | 33 |
| 2018 | 13 |
| 2017 | 18 |
Showing 10 of 36 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 43 trials still running at the 2026-10-09 snapshot; registered median of 36 months across 311 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (629)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Best Practice (which may include intravenous Alteplase) | Lung Neoplasms | Phase 3 | 4 |
| CYCLOPHOSPHAMIDE | Leukemia, Myeloid, Acute | Phase 3 | 8 |
| CYCLOPHOSPHAMIDE | Anemia | Phase 3 | 7 |
| CYCLOPHOSPHAMIDE | Anemia, Aplastic | Phase 3 | 5 |
| Best Practice (which may include intravenous Alteplase) | Colonic Neoplasms | Phase 3 | 1 |
Showing 5 of 629 active programs.
Approved assets (151)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Nitrofurantoin | 1 |
| CLINDAMYCIN | 1 |
| Therapeutic Testosterone | 1 |
| Trimethoprim / Sulfamethoxazole | 1 |
| Ertapenem | 1 |
Showing 5 of 151 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 20% hit target (n=126) | 27% on time (n=116) |
Journals published in (87)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Clinical cancer research : an official journal of the American Association for Cancer Research | 11 |
| Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 6 |
| Pediatric blood & cancer | 5 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 4 |
| British journal of cancer | 3 |
Showing 5 of 87 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2 | 1 | 2025-10-28 |
Financing and grant events (406)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-09-18 | NIH grant | 680,562 | Reporter |
| 2025-09-16 | NIH grant | 584,113 | Reporter |
| 2025-09-12 | NIH grant | 816,307 | Reporter |
| 2025-09-11 | NIH grant | 565,641 | Reporter |
| 2025-09-11 | NIH grant | 168,448 | Reporter |
Showing 5 of 406 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Organization relationships (50)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Bristol Myers Squibb Co | Co sponsors trial with | 6 |
| Beth Israel Deaconess Medical Center | Co sponsors trial with | 3 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 3 |
| Ludwig Cancer Research | Co sponsors trial with | 2 |
| The University of Texas System | Co sponsors trial with | 2 |
Showing 5 of 50 relationships.
Latest dated events (856)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-11-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 856 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| ROSWELL PARK CANCER INSTITUTE | Certificate of compliance | Active |
Biomarker capability evidence (1,045)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ABO | Trial sponsor | Named in trial inclusion criteria |
| AFP | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 1,045 evidence rows.
Biomarkers this organization publishes on (818)
Shown in this order: most publications first.
Showing 5 of 818 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.